Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESB-Sterno: Ropivacaine ESPB for Post-Sternotomy Pain
NCT05160298Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ropivacaine in postoperative pain, sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Change of pain score during cough at 48 hours. Started Oct 2021; status: completed.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05160298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160298.